NCNA - NuCana plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.47
+0.54 (+3.62%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close14.93
Open16.00
Bid9.20 x 1000
Ask16.30 x 800
Day's Range14.94 - 16.00
52 Week Range10.37 - 32.00
Volume2,902
Avg. Volume56,045
Market Cap490.956M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.63
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2,537.30
  • GlobeNewswire11 days ago

    NuCana Reports First Quarter 2019 Financial Results and Provides Business Update

    Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, May 14,.

  • GlobeNewswire2 months ago

    NuCana to Participate in the William Blair 3rd Late-Stage Therapeutics Conference

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the William Blair 3rd Late-Stage Therapeutics Conference in New York, NY. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • Introducing NuCana (NASDAQ:NCNA), The Stock That Dropped 10% In The Last Year
    Simply Wall St.2 months ago

    Introducing NuCana (NASDAQ:NCNA), The Stock That Dropped 10% In The Last Year

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Over the last month the NuCana plc (NASDAQ:NCNA) has been much stronger than before, rebounding by 43%. But that does...

  • Will NuCana Continue to Surge Higher?
    Zacks2 months ago

    Will NuCana Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in NuCana.

  • GlobeNewswire3 months ago

    NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update

    Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, March 07,.

  • GlobeNewswire3 months ago

    NuCana to Present at the Cowen and Company 39th Annual Health Care Conference

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Cowen and Company 39th Annual Health Care Conference in Boston, MA. The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com.

  • GlobeNewswire3 months ago

    NuCana to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019

    NuCana plc (NASDAQ:NCNA) today announced that two abstracts related to NUC-3373 were selected for presentation at the AACR Annual Meeting 2019 to be held March 29 to April 3, 2019, in Atlanta, Georgia.  NUC-3373, NuCana’s second ProTide™ in clinical development, is a transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU), one of the most widely prescribed anti-cancer agents. NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer.

  • GlobeNewswire4 months ago

    NuCana plc Announces Withdrawal of Public Offering of ADSs

    NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company (the “Company”) focused on significantly improving treatment outcomes for patients with cancer, announced today that it has withdrawn the proposed underwritten offering of American Depositary Shares (“ADSs”).  The Company believes it is not in the best interest of its shareholders to raise equity capital in the current market environment.  The Company remains well capitalized with a cash position of approximately £77 million as of December 31, 2018 to fund its key programs. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTideTM technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

  • GlobeNewswire4 months ago

    NuCana plc Announces Proposed Public Offering of ADSs

    NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that it intends to sell, subject to market and other conditions, $75 million of American Depositary Shares (“ADSs”) representing ordinary shares of NuCana on the Nasdaq Global Select Market in an underwritten U.S. public offering. In addition, NuCana intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of ADSs at the offering price. All of the ADSs are being offered by NuCana. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Amarin Down on Lower '19 View, Posts Preliminary '18 Results
    Zacks5 months ago

    Amarin Down on Lower '19 View, Posts Preliminary '18 Results

    Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.

  • GlobeNewswire6 months ago

    NuCana to Participate in Citi's 2018 Global Healthcare Conference

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at Citi's 2018 Global Healthcare Conference in New York, NY on Wednesday, December 5, 2018. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire6 months ago

    NuCana Reports Third Quarter 2018 Financial Results and Provides Business Update

    Favorable Data Presented at ESMO on NUC-1031 (Acelarin®) and NUC-3373 First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer Initiation of Phase.

  • GlobeNewswire6 months ago

    NuCana to Participate in the 2018 Evercore ISI HealthCONx Conference

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 2018 Evercore ISI HealthCONx Conference in Boston, MA on Tuesday, November 27, 2018. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire7 months ago

    NuCana to Participate in the Jefferies 2018 London Healthcare Conference

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2018 London Healthcare Conference in London, UK. The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire7 months ago

    NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer

    This study is evaluating NUC-3373 in combination with other agents typically administered with 5-fluorouracil (5-FU) in patients with advanced colorectal cancer. NUC-3373 is NuCana’s ProTide transformation of the active anti-cancer metabolite of 5-FU.

  • NuCana Sees Hammer Chart Pattern: Time to Buy?
    Zacks7 months ago

    NuCana Sees Hammer Chart Pattern: Time to Buy?

    NuCana PLC has been struggling lately, but the selling pressure may be coming to an end soon.

  • Better Know Biotech: 2 Stocks You've Got to Know About
    Motley Foollast year

    Better Know Biotech: 2 Stocks You've Got to Know About

    These two small-cap biotech stocks could be about to make it big.